Celldex Therapeutics, Inc.

Celldex did not report revenue, EPS, or gross margin on this call. The key hard number disclosed was year-end 2021 cash of $408 million, which management said supports an expected runway through the end of 2025. Operationally, management reported that the Phase 1 subcutaneous CDX-0159 study enrolled four cohorts of eight volunteers each, with six active and two placebo per cohort, and that the chronic tox study used 10 or 75 mg/kg dosing every two weeks for six months. Forward-looking guidance was that Phase 2 CSU and CIndU trials should initiate next quarter, the EoE Phase 2 study should start in the fourth quarter, and data from the CSU multiple-ascending-dose IV study should be submitted for presentation at EAACI 2022 in July.

Anthony Marucci framed 2021 as a very strong year, emphasizing that the company generated promising clinical data and strengthened the balance sheet through a follow-on offering. He stressed that CDX-0159’s profile is becoming more differentiated because it targets the mast cell itself, not just receptors on the cell, and said the subcutaneous formulation is a key step toward more convenient patient administration and eventual commercialization. His tone was upbeat and focused on execution across multiple upcoming studies, with confidence that the current data package supports the next development stage.

No CFO spoke on the call, but management gave finance and development updates tied to cash and operating readiness. Anthony Marucci said the company ended 2021 with $408 million in cash and expects runway through 2025. He also noted that in Q1 2022 Celldex began transferring CDX-0159 manufacturing to a CMO to optimize and scale the process for late-stage trials and future commercialization.

Analysts focused heavily on whether additional Phase 1b dose data are needed before Phase 2. Management said the 4.5 mg/kg CSU cohort is not required to move ahead, and that the 3 mg/kg IV data plus the subcutaneous 300 mg tryptase suppression are enough to support progression. Questions also probed safety and reproductive findings: management said mild heme changes were consistent with prior IV experience, no female reproductive histology issues were seen, and spermatogenesis effects in primates were expected, potentially reversible, and not yet fully characterized until antibody clearance occurs. On EoE, management said they do not know of a predictive biomarker yet and plan to enroll biologic-eligible, clearly diagnosed patients first, then learn which biomarkers may be useful later.